Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-254-7 | CAS number: 1117-86-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Octane-1,2-diol
- EC Number:
- 214-254-7
- EC Name:
- Octane-1,2-diol
- Cas Number:
- 1117-86-8
- Molecular formula:
- C8H18O2
- IUPAC Name:
- octane-1,2-diol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Wistar Han rats with appropriate bodyweight at study start.
- Source: Charles River, Wilmington MA, USA
- Age at study initiation (treatment start): 7-9 weeks.
- Assignment to dose groups: Randomization by a computer-generated random algorithm
- Weight at study initiation (treatment start): Males: minimum 217 g, maximum 247 g,
Females: minimum 158 g, maximum 180 g.
- Housing: In a single experimental room, in groups of 2/cage by sex in polysulfone cages with stainless steel top grill.
During urine collection individual housing in special cages (overnight, water allowed, prior to sacrifice)
- Bedding material: steam sterilized clean corn cob
- Diet (ad libitum)*: Pelleted Teklad Certified Global 14% Protein rodent maintenance diet, Harlan, 5800 AN Venray, The Netherlands
- Water (ad libitum): Deep bore-well water passed through activated charcoal and exposed to UV rays
- Acclimation period: 5 days before treatment start, after clinical examination for health and suitability of all animals.
- Animal wellfare: AAALAC-approved laboratory in accordance with the USA Animal Protection Law.
Routine analysis of the batch of diet used and of water produced results within acceptable ranges.
Animals were fasted overnight (water was available ad libitum) prior to blood sampling for haematology and clinical biochemistry at the end of the treatment period).
ENVIRONMENTAL CONDITIONS (continuously monitored)
The animal room was maintained at (target ranges for temperature and relative humidity):
- Temperature (°C): 19 - 24°C
- Relative Humidity (%): 57 - 67 %
- Photoperiod (artificial lighting): 12 hrs day / 12 hrs night
- Rate of air exchange: 13 to 14 changes/h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Remarks:
- PEG 300
- Details on oral exposure:
- - Concentration in vehicle: The concentration of the test material in vehicle varied between dose groups thus allowing constant dosage volume in terms of mL/kg bw/day. Concentrations amounted to 15, 30, and 100 mg/ml vehicle, accordingly.
- Amount (dose volume by gavage): 10 mL/kg bw/day.
- Dosing formulations were prepared fresh weekly.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- For analysis of the test substance in the vehicle GC / FID was used with a DB-35 column (30 m long, 0.53 mm i.d., 0.5 μm film thickness). The analytical method was validated. The mean contents of the test substance in dose formulations were found to be well within the acceptance limit (within +/- 15%) of dose theoretical concentration; the relative standard deviation was equal to or less than 10%.
- Duration of treatment / exposure:
- Animals were dosed for 90 consecutive days.
- Frequency of treatment:
- Once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10 animals
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - dose selection was based on the result of the 28 day study
- study design was according to OECD 408 guideline - Positive control:
- not applicable
Examinations
- Observations and examinations performed and frequency:
- The following observations and examinations were performed on all animals:
- Mortality/morbidity: twice daily
- General clinical observations: twice daily (pre and post dose) during the first 26 days, then three times daily on Treatment Days 27-90.
- Detailed clinical observations (in their home cages, in standard arena outside the home cage and in the hand, in random sequence):
once before treatment start and once per week until Week 13; in Week 13 observation was carried out twice.
- Functional observation battery (FOB)*: During treatment week 12.
- Body weights: Weekly and before necropsy
- Food consumption: Weekly
- Haematology/Clinical chemistry
(after overnight fasting with water available ad libitum)** , all surviving animals: At completion of the treatment period (Day 91).
* FOB including sensory reactivity tests (reflexes), appearance, behavioural, respiratory and a number of other relevant parameters from a modified
Irvin screen, landing hindlimbs footsplay, fore and hindlimb grip strength and locomotor activity (over 60 minutes).
**Hematology parameters examined:
Red blood cell count, hemoglobin concentration, hematocrit value, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, reticulocyte count, white blood cell count, differential leukocyte counts, prothrombin time, activated partial thromboplastin time.
**Blood chemistry parameters examined:
Glucose, urea, creatinine, total bilirubin, total cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, glutamate dehydrogenase, creatine kinase, alkaline phosphatase, sodium, potassium, chloride, calcium, inorganic phosphorus, total protein, albumin, globulin. - Sacrifice and pathology:
- All surviving animals were killed on Day 91 after 90 consecutive days of oral (gavage) treatment.
- Sacrifice and gross pathology, i.e. full macroscopic external and internal examination with tissue collection, on all animals.
- Organs Weights: Brain, heart, liver, spleen, thymus, adrenals, kidneys, testes, epididymides, ovaries, lungs, pituitary, prostate, seminal vesicles and coagulating glands, thyroid and parathyroid, uterus with cervix.
- Histopathology on the vehicle control and 1000 mg/kg bw/day groups (organs microscopically examined):
Adrenal glands; Bone marrow; Brain [cerebrum, cerebellum, pons, medulla oblongata]; Caecum; Colon; Diaphragm; Duodenum; Epididymides; Esophagus; Eyes with optic nerve; Femoral muscles; Femur bone with joint; Heart; Ileum with Peyer's patches; Jejunum; Kidneys; Liver; Lungs; Lymph nodes – mandibular, mesenteric; Ovaries; Pancreas; Prostate gland; Pituitary; Preputial gland; Rectum; Salivary gland; Sciatic nerve; Seminal vesicles; Skin; Spinal cord -cervical, midthoracic, lumbar; Spleen; Sternum with marrow; Stomach; Testes; Thymus; Thyroid including parathyroid; Trachea; Urinary bladder; Uterus with cervix; Vagina; gross lesions. - Other examinations:
- none
- Statistics:
- The Data captured using Provantis™ for the parameters namely body weights, food consumption and organ weights were analyzed using built-in statistical tests. Derived data like net body weight change and organ weight ratios were also analyzed using above mentioned methods.
The statistical analysis of the experimental data captured other than Provantis™, was carried out using the developed and validated package in Excel and/or using licensed copies of SYSTAT Statistical package Ver.12.0. All quantitative variables like neurological observations (neuromuscular observation and body temperature) and clinical pathology (haematology, coagulation and clinical chemistry) data was tested for normality and homogeneity of variances (Levene’s test) within the group before performing a one-factor ANOVA modeling by treatment groups. Comparison of means between treatment groups and control group was done using Dunnett’s test when the overall treatment, ‘F’ test is found to be significant.
All analyses and comparisons were evaluated at the 5% (P<0.05) level.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- semi-solid feces in 8/10 males at 1000 mg/kg/day on few occasions in the first week considered as adverse effect.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One female of high dose group found dead on Day 68; death was due to misdosing / intubation error.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Significantly lower mean body weights and body weight gains were observed during several weeks in males and females at 300 and 1000 mg/kg bodyweight/day. See attached Tables and Figures in "Attached background material"
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significantly lower food consumption was observed in males during weeks 1, 8 and 12 and in females during weeks 1 and 8 at 1000 mg/kg Bwt/day.See attached Tables in "Attached background material"
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Food efficiency was not determined in the study. However, calculation of food efficiency based on available data indicates a clear reduction of efficiency with increasing dose.
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Weights of male and female reproductive organs did not show significant differences between control and dosed animals up to and including the highest dose level (see attached Tables on organ weights in "Attached background material"
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 150 - < 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
Target system / organ toxicity
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- System:
- other: body weight gain
- Organ:
- other: body weight gain
- Treatment related:
- yes
- Dose response relationship:
- yes
Applicant's summary and conclusion
- Conclusions:
- In this well performed sub-chronic oral toxicity study in rats no systemic toxic effects to organs or blood parameters were observed. Also no effects on neurobehaviour were observed. The only significant effects observed were related to body weight and body weight gain in males and females of the mid and high dose groups. Based on these observations the NOAEL was derived at the low dose group, i.e. 150 mg/kg bodyweight/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.